Article
A decrease in ubiquitination and resulting prolonged life-span of KIT underlies the KIT overexpression-mediated imatinib resistance of KIT mutation-driven canine mast cell tumor cells.
Oncology reports - 1 Oct 2017
Kobayashi Masato, Kuroki Shiori, Kurita Sena, Miyamoto Ryo, Tani Hiroyuki, Tamura Kyoichi, Bonkobara Makoto
Abstract excerpt
Overexpression of KIT is one of the mechanisms that contributes to imatinib resistance in KIT mutation-driven tumors. Here, the mechanism underlying this overexpression of KIT was investigated using an imatinib-sensitive canine mast cell tumor (MCT) line CoMS, which has an activating mutation in KIT exon 11. A KIT-overexpressing imatinib-resistant subline, rCoMS1, was generated from CoMS cells by their continuous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.